K Pharma,Inc. Logo

K Pharma,Inc.

Develops iPS cell-based drugs and regenerative medicine for central nervous system disorders.

4896 | T

Overview

Corporate Details

ISIN(s):
JP3280900006
LEI:
Country:
Japan
Address:
港区六本木七丁目7番7号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

K Pharma, Inc. is a biotechnology company established as a spin-off from the Keio University School of Medicine to commercialize research in induced pluripotent stem (iPS) cell technology. The company engages in the research, development, manufacturing, and sale of pharmaceuticals and regenerative medicine products. Its business is centered on two key areas: iPS drug discovery, which utilizes disease-specific iPS cells to develop new therapies, and regenerative medicine. The company's primary therapeutic focus is on the central nervous system (CNS), developing applications for nerve regeneration to treat conditions such as spinal cord injuries and cerebral infarctions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-06 07:30
Registration Form
有価証券届出書(組込方式)
Japanese 282.2 KB
2025-08-14 02:30
Interim Report
半期報告書-第9期(2025/01/01-2025/12/31)
Japanese 179.3 KB
2025-08-14 02:30
Interim Report
確認書
Japanese 8.8 KB
2025-03-28 02:01
Regulatory News Service
臨時報告書
Japanese 24.2 KB
2025-03-28 02:00
Regulatory News Service
内部統制報告書-第8期(2024/01/01-2024/12/31)
Japanese 22.4 KB
2025-03-28 02:00
Annual Report
有価証券報告書-第8期(2024/01/01-2024/12/31)
Japanese 1.5 MB
2025-03-28 02:00
Regulatory News Service
確認書
Japanese 8.8 KB
2024-08-14 08:00
Interim Report
確認書
Japanese 8.9 KB
2024-08-14 08:00
Interim Report
半期報告書-第8期(2024/01/01-2024/12/31)
Japanese 182.0 KB
2024-05-14 02:00
Quarterly Report
四半期報告書-第8期第1四半期(2024/01/01-2024/03/31)
Japanese 136.5 KB
2024-05-14 02:00
Report Publication Announcement
確認書
Japanese 8.8 KB
2024-03-29 02:30
Post-Annual General Meeting Information
臨時報告書
Japanese 22.6 KB
2024-03-28 07:01
Registration Form
確認書
Japanese 8.8 KB
2024-03-28 07:00
Governance Information
内部統制報告書-第7期(2023/01/01-2023/12/31)
Japanese 22.4 KB
2024-03-28 07:00
Registration Form
有価証券報告書-第7期(2023/01/01-2023/12/31)
Japanese 1.5 MB

Automate Your Workflow. Get a real-time feed of all K Pharma,Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for K Pharma,Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for K Pharma,Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

IMMUCELL CORP /DE/ Logo
Develops biotech health products for disease prevention in dairy and beef cattle.
United States of America
ICCC
Immuneering Corp Logo
Clinical-stage oncology firm using bioinformatics to develop oral MEK inhibitors for solid tumors.
United States of America
IMRX
ImmuneOncia Therapeutics, Inc. Logo
A biopharma firm developing immune checkpoint inhibitors for cancer immunotherapy.
South Korea
424870
ImmunityBio, Inc. Logo
Develops immunotherapies activating the immune system to fight cancer and infectious diseases.
United States of America
IBRX
Immuno-Biological Laboratories Co., Ltd. Logo
Develops and supplies immunological reagents and diagnostics for research and drug discovery.
Japan
4570
Immunocore Holdings plc Logo
Pioneering TCR bispecific immunotherapies for cancer, infectious, and autoimmune diseases.
United States of America
IMCR
Immunome Inc. Logo
Develops targeted oncology therapies, like ADCs, for cancers with high unmet needs.
United States of America
IMNM
Immunovant, Inc. Logo
Developing novel, FcRn-targeted therapies for people with autoimmune diseases.
United States of America
IMVT
Immuron Ltd Logo
Develops oral antibodies from bovine colostrum for digestive and immune health.
United States of America
IMRN
IMPACT BIOMEDICAL INC. Logo
Develops biopharma, preservatives, and bioplastics for healthcare and pathogen protection.
United States of America
IBO

Talk to a Data Expert

Have a question? We'll get back to you promptly.